|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.09 USD | +2.41% |
|
-9.16% | +5.67% |
| Jun. 29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| Jun. 16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,094 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 6.75% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 1,601 | 1,723 | 1,820 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 14.62% | 7.63% | 5.64% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -8.31x | -9.92x | -12.7x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 3.97x | 4.45x | 4.98x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.2x | 0.6x | 0.6x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 4.68x | 3.52x | 2.79x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 3.58x | 2.9x | 2.42x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -6.5x | -10.6x | -23.7x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -6.14x | -9.79x | -19.9x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -9.1x | -14.9x | -25.9x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -11% | -6.72% | -3.86% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.244 | -1.88 | -1.464 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 447.6 | 594.6 | 751.5 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -246.2 | -163.3 | -76.84 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -260.9 | -175.9 | -91.43 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -244.1 | -158.9 | -136.3 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -493.5 | -371.4 | -274.2 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 18.64 | 18.64 | 18.64 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 112,355 | - | - |
| Announcement Date | 3/1/22 | 3/1/23 | 2/27/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -8.31x | 3.58x | -6.5x | -.--% | 2.09B | |
| 17.64x | 3.78x | 9.76x | 0.58% | 67.88B | |
| 26.33x | 5.45x | 16.01x | 0.6% | 53.23B | |
| 37.7x | 12.83x | 24.43x | -.--% | 48.71B | |
| -43.2x | 3.1x | 9.18x | 3.5% | 38.98B | |
| 24.81x | 3.46x | 11.92x | -.--% | 29.55B | |
| 67.61x | 3.45x | 25.63x | -.--% | 23.75B | |
| -6.42x | 8.92x | -5.49x | -.--% | 22.07B | |
| 64.54x | 6.33x | 43.58x | -.--% | 19.84B | |
| 24.4x | 5.22x | 13.67x | -.--% | 16.57B | |
| Average | 20.51x | 5.61x | 14.22x | 0.47% | 32.27B | |
| Weighted average by Cap. | 20.50x | 5.87x | 15.43x | 0.64% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
